<DOC>
	<DOCNO>NCT00018447</DOCNO>
	<brief_summary>This study design determine combine parathyroid ( PTH 1-34 ) fluoride ( MFPSR ) therapy cyclic treatment regimen : ( 1 ) produce great increase bone density spine would produce either treatment alone ; ( 2 ) prevent resistance ( i.e. , decrease bone formation increase bone density ) observe within 18-24 month PTH therapy ; ( 3 ) eliminate calcium deficiency osteomalacia occur fluoride ; ( 4 ) prevent excessive bone fluoride content ; ( 5 ) result increase bone density maintain treatment discontinue .</brief_summary>
	<brief_title>Combination Osteogenic Therapy Established Osteoporosis</brief_title>
	<detailed_description>This 3-yr , single center , open label , active control , randomize study approximately 99 postmenopausal female osteoporosis spine femoral neck . Patients assign 1 3 group : 1 ) PTH 1-34 ; 2 ) Fluoride ; 3 ) PTH fluoride . The treatment period 3 year 3-month cycle therapy . PTH administer subcutaneously injection 600 unit daily 28 day first month 3-month cycle . Fluoride administer orally one 76mg tablet twice daily ( provide 20 mg fluoride/day ) , last 2 month cycle . Calcium provide 800mg/day month 1 1500-2000mg month 2 3 cycle .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>Female , age 6080 , Postmenopausal great equal 5 year , BMD 2.5 4.0 lumbar spine femoral neck one standard deviation young adult mean site , 2.0 fracture . Vertebral fracture 01 . More 1 vertebral fracture lumbar spine 4 fracture TL spine . Weight le 45 kg 80 kg , 25 % ideal body weight . Present cardiac disease present . Diseases condition know affect bone metabolism . Therapies drug affect bone metabolism within 6 month . Fluoride Biophosphonates time .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>osteoporosis</keyword>
</DOC>